In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae

Journal of Microbiology, Immunology and Infection

Volumn 41, Issue 4, 2008, Pages 332-336

  Ku, Yee Huang ^a   Chuang, Yin Ching ^a   Yu, Wen Liang ^a,b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Beta lactamase resistance; Beta lactamases; Enterobacteriaceae; Microbial sensitivity tests; Minocycline

Indexed keywords

CEFOTAXIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; TIGECYCLINE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; EPSILOMETER TEST; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; SERRATIA MARCESCENS; TAIWAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SERRATIA MARCESCENS; TAIWAN;

EID: 57649116090     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A; Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Chemother. 2005;49:2122-5.
2. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56:52-9.
3. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-86.
4. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-12.
5. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-7.
6. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353-65.
7. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al; SENTRY Asia-Pacific Participants. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52:323-9.
8. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents. 2005;26:463-72.
9. Yan JJ, Ko WC, Tsai SH, Wu HM, Jin YT, Wu JJ. Dissemination of CTX-M3 and CMY-2 beta-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol. 2000;38:4320-5.
10. Yan JJ, Wu SM, Tsai SH, Wu JJ, Su IJ. Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. Antimicrob Agents Chemother. 2000;44:1438-42.
11. Cheng KC, Chuang YC, Wu LT, Huang GC, Yu WL. Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn J Infect Dis. 2006;59:147-52.
12. Wu LT, Tsou MF, Wu HJ, Chen HE, Chuang YC, Yu WL. Survey of CTX-M3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan. Diagn Microbiol Infect Dis. 2004;49:125-9.
13. Yu WL, Cheng KC, Chi CJ, Chen HE, Chuang YC, Wu LT. Characterisation and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacter cloacae isolates from a district teaching hospital in Taiwan. Clin Microbiol Infect. 2006;12:579-82.
14. Ma L, Chang FY, Fung CP, Chen TL, Lin JC, Lu PL, et al. Variety of TEM-, SHV-, and CTX-M-type beta-lactamases present in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from Taiwan. Microb Drug Resist. 2005;11:31-9.
15. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001;7:333-6.
16. Tzouvelekis LS, Tzelepi E, Prinarakis E, Gazouli M, Katrahoura A, Giakkoupi P, et al. Sporadic emergence of Klebsiella pneumoniae strains resistant to cefepime and cefpirome in Greek hospitals. J Clin Microbiol. 1998;36:266-8.
17. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518-24.
18. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother. 2003;47:400-4.
19. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents. 2005;25:185-92.
20. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005;56:611-4.
21. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard, 7th ed. CLSI document M7-A7. Wayne, PA: Clinical Laboratory Standards Institute; 2006.
22. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th informational supplement. CLSI document M100-S16. Wayne, PA: Clinical Laboratory Standards Institute; 2006.
23. Tygacil (tigecycline) for injection [package insert]. Philadelphia: Wyeth Pharmaceuticals Inc; 2005.
24. Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol. 2005;5:452-8.
25. Yu WL, Chuang YC, Walther-Rasmussen J. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect. 2006;39:264-77.
26. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2001;1:464-9.
27. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy. 2000;20(9 Pt 2):219S-23S; discussion 224S-28S.
28. Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des. 1998;4:119-32.
29. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbial Infect Dis. 2005;52:215-27.
30. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GA-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis. 2000;36:19-36.
31. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41(Suppl 5):S303-14.
32. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2005;49:1017-22.
33. Liu PY, Tung JC, Ke SC, Chen SL. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a district hospital in Taiwan. J Clin Microbiol. 1998;36:2759-62.
34. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341-5.
35. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase- producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006;50:2695-9.